December 2022
| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| 22072 | Eladocagene exuparvovec | Upstaza® | For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. | __ | 23rd December 2022 |  |
| 22015 | Tixagevimab /cilgavimab | Evusheld® | For the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. | NCPE Assessment Process Complete | 22nd December 2022 | |